TD Cowen analyst Charles Rhyee raised the firm’s price target on CVS Health (CVS) to $80 from $73 and keeps a Buy rating on the shares. The firm said it remains a Best Idea for 2025 and while a high risk pick, they see potential upside of +40% worth it. We view 2024 as a bottom for shares as CVS has set itself up for a significant MA turnaround in 2025 after a successful 2025 bid process and redesign of MA benefits.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target lowered to $64 from $72 at Piper Sandler
- Trump Weekly: Trump looks to drop EV tax credit, fuel-efficiency requirements
- Trump Trade: Transition team weighing White House crypto role
- CVS (NYSE:CVS), UnitedHealth and Cigna File Suit Against the Federal Trade Commission
- Kennedy Jr. considers upheaval to U.S. Medicare billing system, FT says